Foreign media: The US government cancels more than 700 million dollars in funding for Moderna's avian flu vaccine, sparking controversy.

According to Reuters and the U.S. news website Axios, the American pharmaceutical company Moderna announced on May 28th that the Trump administration had canceled a contract with the company to advance the development of a human avian influenza vaccine. This move has sparked controversy, with experts criticizing it as potentially "abandoning a tool to quickly respond to an outbreak of avian influenza." Reuters reported that Moderna had received $590 million in funding from the Biden administration in January to advance avian influenza vaccine research and support the expansion of clinical research to cover five additional influenza subtypes. In addition, the U.S. Department of Health and Human Services had also provided the company with $176 million last year to complete the later development and testing of an mRNA-based vaccine for the H5N1 avian influenza. The total amount of these two funding allocations exceeded $700 million.